Therapeutic management and comorbidities in opiate-dependent patients undergoing a replacement therapy programme in Spain: The PROTEUS study

Heroin Addiction and Related Clinical Problems

Volumn 13, Issue 3, 2011, Pages 5-16

  Roncero, Carlos ^a,b   Fuste, Gideoni ^a   Barral, Carmen ^a   Rodríguez Cintas, Laia ^a   Martínez Luna, Nieves ^a   Eiroa Orosa, Francisco José ^a,b   Casas, Miguel ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Infectious comorbidites; Opiate dependence; Psychiatric comorbidities; Replacement therapies; Therapeutic management

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; DIAMORPHINE; METHADONE; MORPHINE;

ADULT; ALCOHOL ABUSE; ANXIETY DISORDER; ARTICLE; BENZODIAZEPINE DEPENDENCE; CANNABIS ADDICTION; COCAINE DEPENDENCE; COMORBIDITY; CROSS-SECTIONAL STUDY; DESCRIPTIVE RESEARCH; DISSOCIATIVE DISORDER; EATING DISORDER; FEMALE; HEALTH PROGRAM; HEPATITIS C; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; MOOD DISORDER; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPIATE ADDICTION; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOSIS; REPLACEMENT THERAPY PROGRAMME; SCHIZOPHRENIA; SPAIN;

EID: 84983394248     PISSN: 15921638     EISSN: 25314122     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. American Psychiatric Association. (2000). Diagnostic and Statistical Manual of Mental Disorders, Fourth edition, Text Revision (DSM-IVTR). Washington, DC: American Psychiatric Press.
2. Álvarez F. J., González-Saíz F., Meana J. J., Pineda J., & Roncero C. (2005). [SET position paper: buprenorphine in the treatment of opioid dependence in Spain]. Trastornos adictivos, 7, 44-46.
3. Andrews Avorn J., Bortnichak E. A., Chen R., Dai W. S., Dieck G. S., Edlavitch S., Freiman J., Mitchell A. A., Nelson R. C., Neutel C. I., Stergachis A., Strom B. L., Walker A. M., & ISPE. (1996). Guidelines for Good Epidemiology Practices for drug, device, and vaccine research in the United States. Pharmacoepidemiol Drug Saf, 5 (5), 333-338.
4. Astals M., Domingo-Salvany A., Buenaventura C. C., Tato J., Vazquez J. M., Martín-Santos R., & Torrens M. (2008). Impact of substance dependence and dual diagnosis on the quality of life of heroin users seeking treatment. Subst Use Misuse, 43 (5), 612-632.
5. Astals M., Díaz L., Domingo-Salvany A., Martín-Santos R., Bulbena A., & Torrens M. (2009). Impact of co-occurring psychiatric disorders on retention in a methadone maintenance program: an 18-month follow-up study. Int J Environ Res Public Health, 6 (11), 2822-2832.
6. Bacha J., Reast S., & Pearlstone A. (2010). Treatment practices and perceived challenges for European physicians treating opioid dependence. Heroin Addict Relat Clin Probl, 12 (3), 9-19.
7. Ball J. C., & Ross A. (1991). The effectiveness of methadone maintenance treatment. New York: Springer-Verlag.
8. Bao Y. P., Liu Z. M., Epstein D. H., Du C., Shi J., & Lu L. (2009). A meta-analysis of retention in methadone maintenance by dose and dosing strategy. Am J Drug Alcohol Abuse, 35 (1), 28-33.
9. Chaisson R. E., Bacchetti P., Osmond D., Brodie B., Sande M. A., & Moss A. R. (1989). Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA, 261 (4), 561-565.
10. Clausen T., Waal H., Thoresen M., & Gossop M. (2009). Mortality among opiate users: opioid maintenance therapy, age and causes of death. Addiction, 104 (8), 1356-1362.
11. Cornish R., Macleod J., Strang J., Vickerman P., & Hickman M. (2010). Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ, 341, c5475.
12. Domingo-Salvany A., Pérez K., Torrens M., Bravo M. J., Antó J. M., & Alonso J. (1999). Methadone treatment in Spain, 1994. Drug Alcohol Depen, 56, 61-66.
13. Eder H., Jagsch R., Kraigher D., Primorac A., Ebner N., & Fischer G. (2005). Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy. Addiction, 100 (8), 1101-1109.
14. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Annual Report 2010. The state of drugs problem in Europe. Luxembourg: Publications Office of the European Union; 2010. (Accessed on February 2011). Available at: http: //www.emcdda.europa.eu.
15. Fareed A., Casarella J., Amar R., Vayalapalli S., & Drexler K. (2010). Methadone maintenance dosing guideline for opioid dependence, a literature review. J Addict Dis, 29 (1), 1-14.
16. Fernández J., González M., Sáiz P., Gutiérrez E., & Bobes J. (2001). [Influence of psychiatric disorders in the effectiveness of a long-term methadone maintenance treatment]. Actas Esp Psiquiatr, 29 (4), 228-232.
17. Fernández J. J. (2005). [Effectiveness of methadone maintenance programs]. Adicciones, 17 (Suppl 2), 167-180.
18. Fernández J. J., & Gutiérrez E. (2005). [Personality disorders and heroin dependence: a relationship to discover]. Adicciones, 17 (Suppl. 2), 95-110.
19. Fernández A. M., Fernández V., & López J. (2009). [Benzodiazepine use in a sample of patients on a treatment program with opiate derivatives (PTDO)]. Adicciones, 21 (2), 143-146.
20. Ferrari A., Coccia C. P., Bertolini A., & Sternieri E. (2004). Methadone--metabolism, pharmacokinetics and interactions. Pharmacol Res, 50 (6), 551-559.
21. Ferri M., Davoli M., & Perucci C. A. (2010). Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database of Systematic Reviews, 8, CD003410.
22. Gelkopf M., Weizman T., Melamed Y., Adelson M., & Bleich A. (2006). Does psychiatric comorbidity affect drug abuse treatment outcome? A prospective assessment of drug abuse, treatment tenure and infectious diseases in an Israeli methadone maintenance clinic. Isr J Psychiatry Relat Sci, 43 (2), 126-136.
23. Gerra G., Saenz E., Busse A., Maremmani I., Ciccocioppo R., Zaimovic A., Gerra M. L., Amore M., Manfredini M., Donnini C., & Somaini L. (2010). Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance. Prog Neuropsychopharmacol Biol Psychiatry, 35 (2), 483-489.
24. Government Delegation for the National Plan on Drugs (DGPNSD). [National Plan on Drugs. Report 2008]. Madrid: Ministerio de Sanidad y Política Social de España; 2008. Available at: (http: //www.pnsd.msc.es, accessed on February 2011)
25. Government Delegation for the National Plan on Drugs (DGPNSD). [Spanish Observatory on Drugs. Report 2009]. Madrid: Ministerio de Sanidad y Política Social de España; 2009. (Accessed on February 2011). Available at: http: //www.pnsd.msc.es/Categoria2/observa.
26. Gowing L., Ali R., & White J. M. (2009). Buprenorphine for the management of opioid withdrawal. Cochrane Database of Systematic Reviews, 3, CD002025.
27. Grönbladh L., & Gunne L. (1989). Methadoneassisted rehabilitation of Swedish heroin addicts. Drug Alcohol Depen, 24 (1), 31-37.
28. Hubbard R. L., Rachal J. V., Craddock S. G., & Cavanaugh E. R. (1984). Treatment Outcome Prospective Study (TOPS): client characteristics and behaviors before, during, and after treatment. NIDA Res Monogr, 51, 42-68.
29. International Epidemiological Association (IEA). Good epidemiological practice (GEP). IEA guidelines for paper conduct in epidemiologic research. IEA European Federation; November 2007. (Accessed on February 2011). Available at: http: //www.ieaweb.org.
30. Mammen K., & Bell J. (2009). The clinical efficacy and abuse potential of combination buprenorphinenaloxone in the treatment of opioid dependence. Expert Opin Pharmacother, 10 (15), 2537-2544.
31. Mateu G., Astals M., & Torrens M. (2005). [Psychiatric comorbidity and opioid dependence disorder: from diagnosis to treatment]. Adicciones, 17 (Suppl 2), 111-121.
32. Mattick R. P., Breen C., Kimber J., & Davoli M. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews, 3, CD002209.
33. Maxwell S., Shinderman M. S., Miner A., & Bennet A. (2002). Correlation between hepatitis C serostatus and methadone dose requirement in 1, 163 methadone-maintained patients. Heroin Addiction Relat Clin Probl, 4 (2), 5-10.
34. Milby J. B., Sims M. K., Khuder S., Schumacher J. E., & Huggins N. (1996). Psychiatric comorbidity: prevalence in methadone maintenance treatment. Am J Drug Alcohol Abuse, 22 (1), 95-107.
35. National Treatment Agency for Substance Misuse (NTA), Department of Health (England) and the devolved administrations. Drug Misuse and Dependence: UK Guidelines on Clinical Management. London: Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive; 2007. (Accessed on February 2011). Available at: http: //www.nta.nhs.uk.
36. Nicholls L., Bragaw L., & Ruetsch C. (2010). Opioid dependence treatment and guidelines. Journal of Managed Care Pharmacy, 16 (Suppl 1B), S14-21.
37. Okruhlica L., & Klempova D. (2000). Hepatitis C infected patients and higher doses of methadone. Heroin Addict Relat Clin Probl, 2 (2), 57-58.
38. Orman J. S., & Keating G. M. (2009). Spotlight on buprenorphine/naloxone in the treatment of opioid dependence. CNS Drugs, 23 (10), 899-902.
39. Pollack H. A., & D’Aunno T. (2008). Dosage patterns in methadone treatment: results from a national survey, 1988-2005. Health Serv Res, 43 (6), 2143-2163.
40. Puigdollers E., Cots F., Brugal M. T., Torralba L., & Domingo-Salvany A. (2003). [Methadone maintenance programs with supplementary services: a cost-effectiveness study]. Gaceta Sanitaria, 17 (2), 123-130.
41. Puigdollers E., Domingo-Salvany A., Brugal M. T., Torrens M., Alvarós J., Castillo C., Magrí N., Martín S., & Vázquez J. M. (2004). Characteristics of heroin addicts entering methadone maintenance treatment: quality of life and gender. Subst Use Misuse, 39 (9), 1353-1368.
42. Quaglio G., Lugoboni F., Pattaro C., Montanari L., Lechi A., Mezzelani P., & Des Jarlais D. C. (2006). Patients in long-term maintenance therapy for drug use in Italy: analysis of some parameters of social integration and serological status for infectious diseases in a cohort of 1091 patients. BMC Public Health, 6, 216.
43. Rodriguez-Llera M. C., Domingo-Salvany A., Brugal M. T., Silva T. C., Sánchez-Niubó A., Torrens M., & ITINERE Investigators (2006). Psychiatric comorbidity in young heroin users. Drug Alcohol Depend, 84 (1), 48-55.
44. Roncero Alonso C., Sáez Francàs N., Castells X., & Casas M. (2007). Morphine maintenance treatment in opiate dependent patients. Rev Clín Esp, 207 (4), 194-196.
45. Roncero Alonso C., Sáez-Francàs N., Castells X., & Casas M. (2008). [Efficacy and clinical management of buprenorphine]. Trastornos Adictivos, 10 (2), 77-87.
46. Roncero Alonso C., López-Ortiz C., Barral C., Sáez-Francàs N., Rovira M., & Casas M. (2009a). [Concomitant lithium and methadone treatment in a bipolar patient: a case report]. Adicciones, 21 (2), 167-172.
47. Roncero Alonso C., Fuste G., Barral C., Rodríguez-Cintas L., Eiroa-Orosa F. J., & Casas M. (2009b). [Therapeutic management and comorbid psychiatric disorders among opiate dependent patients in replacement therapy programs: the PROTEUS study]. Trastornos Adictivos, 11 (4), 266-267.
48. San Narciso G. I., Gutiérrez E., Sáiz, P. A., González M. P., Bascarán M. T., & Bobes J. (2000). [Assessment of personality disorders in heroin abusers using the International Personality Disorders Examination (IPDE)]. Adicciones, 12 (1), 43-56.
49. Schäfer I., Eiroa-Orosa F. J., Verthein U., Dilg C., Haasen C., & Reimer J. (2010). Effects of psychiatric comorbidity on treatment outcome in patients undergoing diamorphine or methadone maintenance treatment. Psychopathology, 43 (2), 88-95.
50. Skeie I., Brekkle M., Lindbaek M., & Waal H. (2008). Somatic health among heroin addicts before and during opioid maintenance treatment: a retrospective cohort study. BMC Public Health, 8, 43.
51. Strain E. C., Bigelow G. E., Liebson I. A., & Stitzer M. L. (1999). Moderate-vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA, 281 (11), 1000-1005.
52. United Nations Office of Drugs and Crimes (UNODC). World Drug Report 2010. New York: United Nations Publications; 2010. (Accessed on February 2011). Available at: http: //www.unodc.org.
53. Van Den Berg C., Smit C., Van Brussel G., Coutinho R., Prins M., & Amsterdam Cohort. (2007). Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction, 102 (9), 1454-1462.
54. Verthein U., Degkwitz P., Haasen C., & Krausz M. (2005). Significance of comorbidity for the long-term course of opiate dependence. European Addiction Research, 11 (1), 15-21.
55. Wedekind D., Jacobs S., Karg I., Luedecke C., Schneider U., Cimander K., Baumann P., Ruether E., Poser W., & Havemann-Reinecke U. (2010). Psychiatric comorbidity and additional abuse of drugs in maintenance treatment with L-and D, Lmethadone. World J Biol Psychiatry, 11, 390-399.
56. White J. M., & Lopatko O. V. (2007). Opioid maintenance: a comparative review of pharmacological strategies. Expert Opinion on Pharmacotherapy, 8 (1), 1-11.
57. Yancovitz S. R., Des Jarlais D. C., Peyser N. P., Drew E., Friedmann P., Trigg H. L., & Robinson J. W. (1991). A randomized trial of an interim methadone maintenance clinic. Am J Public Health, 81 (9), 1185-91.